Ryuichi Kiyama - Shionogi Sr Division
| SH0 Stock | EUR 12.80 0.10 0.79% |
Insider
Ryuichi Kiyama is Sr Division of Shionogi Co
| Phone | 81 6 6202 2161 |
| Web | https://www.shionogi.com |
Shionogi Management Efficiency
The company has return on total asset (ROA) of 0.1069 % which means that it generated a profit of $0.1069 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2014 %, meaning that it generated $0.2014 on every $100 dollars invested by stockholders. Shionogi's management efficiency ratios could be used to measure how well Shionogi manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Steven Frank | Zoetis Inc | N/A | |
| Torbjrn Hallberg | Swedish Orphan Biovitrum | 54 | |
| Gabriele Ricci | Takeda Pharmaceutical | 45 | |
| Christine Wesstrom | Swedish Orphan Biovitrum | 48 | |
| Salvatore Alesci | Takeda Pharmaceutical | N/A | |
| Thomas Castellano | Catalent | 43 | |
| David Stark | Teva Pharmaceutical Industries | 54 | |
| Norimasa Takeda | Takeda Pharmaceutical | N/A | |
| Aymeric Chatelier | Ipsen SA | 54 | |
| David Loew | Ipsen SA | 56 | |
| Iwaaki Taniguchi | Takeda Pharmaceutical | N/A | |
| Eric Drape | Teva Pharmaceutical Industries | 61 | |
| MBA MBA | Dr Reddys Laboratories | 54 | |
| Philip Wood | Swedish Orphan Biovitrum | 55 | |
| Gary Hendler | Eisai Co | 57 | |
| Eli Shani | Teva Pharmaceutical Industries | N/A | |
| Kathleen Veit | Teva Pharmaceutical Industries | N/A | |
| Konstantina Karampela | Swedish Orphan Biovitrum | N/A | |
| Yanhui Feng | Eisai Co | 51 | |
| Haruhiko Hirate | Takeda Pharmaceutical | 66 | |
| Constantine Saroukos | Takeda Pharmaceutical | 52 | |
Management Performance
Shionogi Leadership Team
Elected by the shareholders, the Shionogi's board of directors comprises two types of representatives: Shionogi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shionogi. The board's role is to monitor Shionogi's management team and ensure that shareholders' interests are well served. Shionogi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shionogi's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kohji Hanasaki, Sr Division | ||
| Isao Teshirogi, CEO Chairman | ||
| Kazuhiro Hatanaka, Sr Division | ||
| Yoshihiro Furuya, VP Office | ||
| Ryuichi Kiyama, Sr Division | ||
| Takeshi Shiota, Ethics Assurance | ||
| John Keller, Sr Unit | ||
| Susumu Mitsumori, VP Department | ||
| Akira Kato, Ltd Co | ||
| Yoshimasa Kyokawa, VP Office |
Shionogi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Shionogi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.44 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 10.75 B | |||
| Shares Outstanding | 298.16 M | |||
| Shares Owned By Insiders | 4.66 % | |||
| Shares Owned By Institutions | 52.77 % | |||
| Price To Earning | 15.37 X | |||
| Price To Book | 2.00 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Shionogi Stock
Shionogi financial ratios help investors to determine whether Shionogi Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shionogi with respect to the benefits of owning Shionogi security.